Novo Nordisk - GLP-1 RAs lawsuits & claim

Novo Nordisk was established in 1923 and is headquartered in Bagsværd, Denmark. The company operates in 80 offices worldwide, but its products reach people in 170 countries.

In the last couple of decades, Novo Nordisk has become one of the leading names for type 2 diabetes and weight loss management medications, which are sold through their line of glucagon-like peptide-1 (GLP-1) receptor agonist medications. These products include:

• Ozempic
• Wegovy
• Rybelsus
• Victoza
• Saxenda

In 2024, a Pennsylvania woman Juanita Gantt filed a lawsuit against Novo Nordisk. She was prescribed Wegovy and, eventually, Ozempic in 2023. That same year, she was found unconscious on the floor by her husband. Upon a doctor’s appointment, it was discovered that parts of her intestines had died.

Novo Nordisk’s medications linked to severe gastrointestinal and vision conditions

GLP-1 RAs mimic a hormone that the body makes naturally. When administered, these medications essentially help regulate blood sugar and control appetite. However, recent findings have shown that GLP-1 RAs can also result in serious health conditions, which include:

• Gastroparesis - The partial or complete paralysis of the stomach, making it difficult for people to digest food.
• Vision loss - Non-arteritic anterior ischemic optic neuropathy (NAION). This is a sudden and painless loss of vision that’s caused by a lack of blood flow to the optic nerve.
• Bowel obstruction - As the stomach’s digestion slows down, the chances of food and bezoar formations blocking your intestines become likely. This results in an uncomfortable feeling of bloatedness, nausea, vomiting, and abdominal pain.

These conditions are dangerous, with gastroparesis and NAION being untreatable. Aside from being costly, these can gravely affect the victim’s quality of life as well.

Novo Nordisk is involved in a multidistrict litigation case

The US Judicial Panel on Multidistrict Litigation (JPML) has consolidated all of these cases into MDL 3094: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION.

Currently, there are over 1,300 pending lawsuits involved in MDL 3094, which further highlights the seriousness of the injuries to the plaintiffs. The eligibility of the lawsuit depends on the following:

• Victim must not have pre-existing gastroparesis, vision loss, or bowel obstruction before taking GLP-1 RA medications.
• Victim must have undergone at least one round of TOzempic, Wegovy, Rybelsus, Victoza, or Saxenda.
• Victim must have been diagnosed with gastroparesis, vision loss, and bowel obstruction after taking GLP-1 RA medications.

Atraxia Law provides legal assistance for weight loss injection claims

Victims who want to take Novo Nordisk to court but are unsure of their case’s eligibility shouldn’t hesitate to reach out to Atraxia Law. Our team of experts can check a claim’s eligibility. If you’re a potential claimant, we’ll put you in contact with an expert attorney immediately.